Diagnostic Imaging Pathways - Hyperaldosteronism (Primary Suspected)
- Pathway Home
- Pathway
- Images
- Teaching Points
- ad_vein
- biochem
- confirm
- ct
- hyp_aldo
- References
- Information for Consumers
- copyright
Pathway Home
Population Covered By The Guidance
This pathway provides guidance on the imaging of adult patients with biochemically confirmed primary hyperaldosteronism.
Date reviewed: January 2012
Date of next review: January 2015
Published: January 2012
Quick User Guide
Move the mouse cursor over the PINK text boxes inside the flow chart to bring up a pop up box with salient points.
Clicking on the PINK text box will bring up the full text.
The relative radiation level (RRL) of each imaging investigation is displayed in the pop up box.
| SYMBOL | RRL | EFFECTIVE DOSE RANGE |
 | None | 0 |
 | Minimal | < 1 millisieverts |
 | Low | 1-5 mSv |
 | Medium | 5-10 mSv |
 | High | >10 mSv |
Images
Image GalleryNote: These images open in a new page | ||
|---|---|---|
| 1a |  |
Adrenal Adenoma Image 1a, b and c (Computed Tomography): There is a 12mm sized rounded hypodense mass lesion noted in the right adrenal gland. There is marked contrast wash-out demonstrated in the lesion which is in keeping with adenoma. |
| 1b |  |
|
| 1c |  |
|
| 1d |  |
Image 1d (Adrenal Vein Sampling): A sample is taken from the left adrenal vein for analysis and comparison to that from the right renal vein. |
| 2a |  |
Adrenocortical Adenoma Image 2a: Adrenalectomy specimen showing a typical adrenocortical adenoma forming a circumscribed and encapsulated mass with a homogenous yellow cut surface. Note the residual adrenal parenchyma at the periphery of the lesion (arrow). |
| 2b |  |
Image 2b (H&E, x2.5) and 2c (H&E, x10): Histological section showing the pushing border between the adenoma and the surrounding parenchyma (arrows) At higher power, the cells form sheets and nests and exhibit uniform nuclei and clear cytoplasm due to their high lipid content.
|
| 2c |  |
|
Teaching Points
Teaching Points
- Indications for screening of suspected hyperaldosteronism
- Hypokalaemic hypertension
- Refractory hypertension
- Presence of an incidentally detected adrenal mass
- Family history of hypertension
- Biochemical confirmation of primary hyperaldosteronism must be confirmed prior to imaging
- CT of the adrenals is the initial imaging modality for localisation of biochemically proven primary hyperaldosteronism
- Adrenal vein sampling should be undertaken to assess for a surgical remedial cause of primary hyperaldosteronism
ad_vein
Adrenal Vein Sampling (AVS)
- Most reliable method to localise the lesion resulting in primary hyperaldosteronism, and will dictate further management 6,8,9,10,12
- Concordance between computed tomography and adrenal vein sampling for the assessment of primary hyperaldosteronism is poor 15
- Adrenal vein sampling is a sensitive test to differentiate aldosterone-producing adenoma (APA) from bilateral hyperplasia 8,9,12
- The aldosterone to cortisol ratio in both adrenal veins is compared. If one side has a concentration more than 2 times the other side, then APA is diagnosed; bilateral adrenal hyperplasia is the diagnosis by default 12
- When successful, AVS unequivocally establishes the presence or absence of unilateral aldosterone production, thus clarifying the choice of therapy - medical or surgical 1
- Disadvantages - invasive, highly operator-dependent, not widely available and carries a finite risk of venous thrombosis, adrenal haemorrhage, and adrenal insufficiency
biochem
Screening for Primary Hyperaldosteronism
- Plasma aldosterone concentration to plasma renin activity ratio (PAC/PRA) is regarded as the screening test of choice for primary hyperaldosteronism (PA) 1,3
- Biochemical diagnosis of primary hyperaldosteronism must be established prior to performing imaging studies to avoid unnecessary surgery because 3% to 7% of patients over the age of 50 have non-functioning adrenal nodules ("incidentalomas") 4
confirm
Confirmatory Testing
- A number of further tests are available to confirm the diagnosis of primary hyperaldosteronism. These include 13
- Fludrocortisone suppression test
- Normal saline infusion
- Oral sodium loading
- In clinical practice however, a properly performed plasma aldosterone:renin concentration (PAC / PRA) particularly in the absence of medications likely to cause false results (such as B-blockers and diuretics) is normally sufficient to make the diagnosis
ct
Computed Tomography (CT)
- Initial imaging modality of choice for localisation of biochemically proven primary hyperaldosteronism 1,2
- Computed Tomography has been shown to have a sensitivity of 50-60% in the detection of adenoma 6,7,8
- Magnetic Resonance Imaging has been shown to have a comparable sensitivity of 70% in detecting adenoma, with a specificity of 100% 14
- Advantages - non-invasive and is useful in mapping the position of veins prior to adrenal vein sampling
hyp_aldo
Primary Hyperaldosteronism
- The incidence of hyperaldosteronism as a cause for hypertension is believed to be more common than previously thought. 2-10% of patients with hypertension have hyperaldosteronism 1
- Imaging is used for localisation of a biochemically proven abnormality 1,2
- The most important distinction to be made is between the two most common
causes of primary hyperaldosteronism 1,2
- Aldosterone producing adenoma (APA) - one third of cases of primary hyperaldosteronism
- Bilateral adrenal hyperplasia or idiopathic hyperaldosteronism (IHA) - two thirds of cases of primary hyperaldosteronism
- Aldosterone producing adenoma is treated surgically and bilateral adrenal hyperplasia is treated medically 1,2
References
References
References are graded from Level I to V according to the Oxford Centre for Evidence-Based Medicine, Levels of Evidence. Download the document
- Thakkar RB, Oparil S. Primary aldosteronism: a practical approach to diagnosis and treatment. J Clin Hypertension. 2001;3(3):189-95. (Review article)
- Ganguly A. Primary aldosteronism. N Engl J Med. 1998;339(25):1828-34. (Review article)
- Soule S, Davidson JS, Rayner BL. The evaluation of primary hyperaldosteronism. S Afr Med J. 2000;90(4):387-94. (Level II/III evidence)
- Bornstein SR, Stratakis CA, Chrousos GP. Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann Intern Med. 1999;130:759-71. (Review article)
- Radin DR, Manoogian C, Nadler JL. Diagnosis of primary hyperaldosteronism: importance of correlating CT findings with endocrinologic studies. AJR Am J Roentgenol. 1992;158:553-7. (Level III evidence)
- Doppman JL, Gill JR Jr, Miller DL, et al. Distinction between hyperaldosteronism due to bilateral hyperplasia and unilateral aldosteronoma: reliability of CT. Radiology. 1992;184:677-82. (Level II evidence). View the reference
- Dunnick NR, Leight GS, Robidoux MA, et al. CT in the diagnosis of primary aldosteronism: sensitivity in 29 patients. AJR Am J Roentgenol. 1993;160:321-4. (Level III evidence)
- Harper R, Ferrett CG, McKnight JA, et al. Accuracy of CT and adrenal vein sampling in the pre-operative sampling localization of aldosterone-secreting adrenal adenomas. Q J Med. 1999;92:643-50. (Level III evidence)
- Magill SB, Raff H, Shaker JL, et al. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab. 2001;86:1066-71. (Level III evidence)
- Ikeda DM, Francis IR, Glazer Gm, et al. The detection of adrenal tumors and hyperplasia in patients with primary aldosteronism: comparison of scintigraphy, CT and MR imaging. AJR Am J Roentgenol. 1989;153:301-6. (Level III evidence)
- Nocaudie-Calzada M, Huglo D, Lambert M, et al. Efficacy of iodine 131 6b-methyl-iodo-19-norcholesterol scintigraphy and computed tomography in patients with primary hypoaldosteronism. Eur J Nucl Med. 1999;26:1326-32. (Level III evidence)
- Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State of the art adrenal imaging. Radiographics. 2001;21:995-1012. (Review article)
- Schirpenbach C, Reincke M. Screening for primary hyperaldosteronism. Best Prac Res Clin Endocrinol Metab. 2006;20(3):369-84. (Review article)
- Sohaib S, Peppercorn P, Allan C. Primary hyperaldosteronism (Conn syndrome): MR imaging findings. Radiology. 2000;214:527-31. (Level IV evidence)
- Nwariaku F, Miller B, Auchus R et al. Primary hyperaldosteronism. Arch Surg. 2006; 141:497-503. (Level IV evidence)
Information for Consumers
Information for Consumers
Information from this website |
Information from the Royal Australian and New Zealand College of Radiologists’ website |
|
Consent to Procedure or Treatment Radiation Risks of X-rays and Scans |
Iodine-Containing Contrast Medium Radiation Risk of Medical Imaging During Pregnancy Radiation Risk of Medical Imaging for Adults and Children |
copyright
Copyright
© Copyright 2015, Department of Health Western Australia. All Rights Reserved. This web site and its content has been prepared by The Department of Health, Western Australia. The information contained on this web site is protected by copyright.
Legal Notice
Please remember that this leaflet is intended as general information only. It is not definitive and The Department of Health, Western Australia can not accept any legal liability arising from its use. The information is kept as up to date and accurate as possible, but please be warned that it is always subject to change
.File Formats
Some documents for download on this website are in a Portable Document Format (PDF). To read these files you might need to download Adobe Acrobat Reader.
